|
13 Sep 2025 |
Eris Lifesciences
|
Consensus Share Price Target
|
1675.90 |
1860.10 |
- |
10.99 |
buy
|
|
|
|
|
08 Aug 2022
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1675.90
|
825.00
|
696.30
(140.69%)
|
Target met |
Buy
|
|
|
|
|
16 May 2022
|
Eris Lifesciences
|
Motilal Oswal
|
1675.90
|
870.00
|
698.30
(140.00%)
|
|
Buy
|
|
|
|
|
05 May 2022
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1675.90
|
850.00
|
672.15
(149.33%)
|
|
Buy
|
|
|
|
|
05 May 2022
|
Eris Lifesciences
|
Motilal Oswal
|
1675.90
|
870.00
|
670.10
(150.10%)
|
|
Buy
|
|
|
|
|
29 Jan 2022
|
Eris Lifesciences
|
BOB Capital Markets Ltd.
|
1675.90
|
890.00
|
698.50
(139.93%)
|
|
Buy
|
|
|
Industry-wide slowdown in cardiometabolic segment (59% revenue share for ERIS) affected Q3 growth
|
|
27 Dec 2021
|
Eris Lifesciences
|
Motilal Oswal
|
1675.90
|
870.00
|
732.45
(128.81%)
|
|
Buy
|
|
|
|
|
07 Dec 2021
|
Eris Lifesciences
|
BOB Capital Markets Ltd.
|
1675.90
|
975.00
|
723.20
(131.73%)
|
|
Buy
|
|
|
ERIS: Foray into India's insulin market
|
|
06 Dec 2021
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1675.90
|
954.00
|
729.65
(129.69%)
|
|
Buy
|
|
|
our positive stance on ERIS given 1) scheduled potential launches, 2) strong pipeline of patent expiration opportunities and 3) rapidly growing new-generation brands along with power brands in core therapies. ERIS's timely strategy of capacity expansion and higher contribution from chronic/sub-chronic products supported by insignificant regulatory risk, allows it to stand ahead in the industry. We have not factored any revenues and expenses from this JV. Maintain our BUY'...
|
|
06 Dec 2021
|
Eris Lifesciences
|
BOB Capital Markets Ltd.
|
1675.90
|
975.00
|
698.15
(140.05%)
|
|
Buy
|
|
|
ERIS enters ten-year, 70:30 JV with MJ Biopharm for marketing rh-insulin, insulin analogues, GLP1 agonists and biosimilars
|
|
02 Nov 2021
|
Eris Lifesciences
|
Prabhudas Lilladhar
|
1675.90
|
954.00
|
803.05
(108.69%)
|
|
Buy
|
|
|
Eris Lifesciences (ERIS) achieved robust Q2 growth and outperformed IPM in chronic segment. We maintain our positive stance given 1) scheduled potential launches, 2) strong pipeline of patent expiration opportunities and 3) rapidly growing new-generation brands along with power brands in core therapies. ERIS's timely strategy of capacity expansion and higher contribution from chronic/sub-chronic products supported by insignificant regulatory risk, allows it to stand ahead in the industry. We expect 18%...
|